Description

Fingolimod (FTY720) is a sphingosine?1?phosphate receptor modulator developed for immunological research, particularly in multiple sclerosis and inflammatory models. It works by sequestering lymphocytes in lymphoid tissues, reducing peripheral immune activity.

The Jielingya formulation provides 0.5?mg Fingolimod HCl per capsule, 14 capsules per blister, 2 blisters per box. Manufactured by Novartis Pharma Stein AG (Switzerland) and repackaged by Novartis China in Beijing.

Approved under NMPA number J20190024, product code 86900100000422.

?? For laboratory research use only. Not for clinical, therapeutic, or diagnostic use.

Fingolimod Hydrochloride Product Specifications

Fingolimod Hydrochloride Mechanism & Research Applications

Fingolimod acts as an S1P receptor modulator, causing internalization of S1P? receptors on lymphocytes, effectively lowering their circulation and modulating immune responses . Widely used in:

• Multiple sclerosis and neuroinflammation models

• Autoimmune disease preclinical studies

• Lymphocyte trafficking and immunosuppression research

• Comparative immunomodulatory drug assays

• Vaccine and toxicology immune-response studies

Fingolimod Hydrochloride Side Effects (Observed in Research Context)

In animal and in vitro studies, potential effects include:

• Transient bradycardia, especially after initial dose

• Increased risk of infection due to immune suppression

• Macular edema and mild visual disturbances

• Liver enzyme elevation and hypertension

• Rare neurological events (e.g. PML) in immunosuppressed models

Researchers should implement proper monitoring protocols, especially for heart rate and immune function.

Safety & Handling

• Use Restriction: Research use only; not approved for therapeutic/clinical use

• PPE: Gloves, lab coat, protective eyewear

• Storage: Room temperature (20–25?°C), low humidity, dark setting

• Disposal: Dispose as pharmaceutical and biohazardous waste

Core Keywords

Fingolimod hydrochloride capsules, Jielingya fingolimod capsules, 0.5?mg fingolimod research, S1P receptor modulator, J20190024 fingolimod China, lab-use fingolimod, Novartis fingolimod repackaged

Research Use Disclaimer

For laboratory research only. This product is not approved for human or veterinary therapeutic, diagnostic, or prophylactic use. Misuse may result in health or legal liabilities. Users must follow institutional biosafety and chemical handling regulations.